Phio Pharmaceuticals Showcases PH-762 Skin Cancer Trial Progress
KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...
JERUSALEM, May 8, 2026 Alpha Tau Medical Ltd. announced the completion of patient enrollment in its ReSTART pivotal clinical...
